3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Colorectal Neoplasms
67
Pancreatic Neoplasms
34
Neoplasm Metastasis
22
Neuroblastoma
21
Neoplasms
16
Colonic Neoplasms
15
Stomach Neoplasms
13
Rectal Neoplasms
13
Esophageal Squamous Cell Carcinoma
9
Sarcoma, Ewing
8
Rhabdomyosarcoma
8
Small Cell Lung Carcinoma
7
Sarcoma
7
Ovarian Neoplasms
6
Lung Neoplasms
6
Cholangiocarcinoma
6
Esophageal Neoplasms
5
Breast Neoplasms
5
Adenocarcinoma Of Esophagus
5
Medulloblastoma
4
Gastrointestinal Neoplasms
4
Endometrial Neoplasms
4
Biliary Tract Neoplasms
4
Adenocarcinoma
4
Recurrence
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Osteosarcoma
3
Glioma
3
Glioblastoma
3
Ganglioneuroblastoma
3
Interventions
Carboplatin
6
pembrolizumab
3
Paclitaxel
3
Observation
3
Capecitabine
3
Azacitidine
3
venetoclax
2
pertuzumab
2
olaparib
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Oxaliplatin
2
Irinotecan
2
Immunotherapy
2
Chemoradiotherapy
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
taxane
1
talazoparib
1
tagraxofusp
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Irinotecan
×
1 year
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled